Clinical trial NCT06897644: Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
Official title: Gemcitabine Plus Nab-PAclitaxel as Switch maiNTEnance Versus cONtinuation of Modified FOLFIRINOX as First-line Chemotherapy in Patients With Advanced Pancreatic Cancer: the PANThEON Phase III Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Pancreatic Adenocarcinoma Advanced or Metastatic
Keywords: first line
mFOLFIRINOX
chemotherapy
pancreas
Gemcitabine with Nab-Paclitaxel
switch maintenance
pancreatic cancer
Lead sponsor: Gruppo Oncologico del Nord-Ovest
Sponsor class: OTHER
Collaborators: name: Rising Tide Foundation
First posted: 2025-03-27
Enrollment: 340
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: PANThEON is a randomized, open-label, multicenter phase III trial aimed at comparing the switch maintenance with gemcitabine plus nab-paclitaxel (ARM B) versus mFOLFIRINOX continuation (ARM A) in terms of overall survival (OS) in patients with unresectable LAD or mPDAC without disease progression following 3 months of induction mFOLFIRINOX triplet chemotherapy.

Detailed description: PANThEON is a randomized, open-label, multicenter phase III trial of switch maintenance with gemcitabine plus nab-paclitaxel (ARM B) versus mFOLFIRINOX continuation (ARM A) in patients with unresectable LAD or mPDAC without disease progression following 3 months of induction mFOLFIRINOX triplet chemotherapy.

The induction chemotherapy regimen will be mFOLFIRINOX as per standard of care. Treatment must be continued for up to a maximum of 14 weeks, corresponding to \~ 6 bi-weekly cycles. A minimum of 4 treatment cycles administered is necessary for the patient to be evaluable for randomization.

Radiological tumor assessment will be performed before the start and after completion of induction chemotherapy. Patients with complete/partial response or stable disease (CR/PR/SD) or without evidence of progressive disease (PD) in case of non-measurable disease will be randomized in a 1:1 ratio.

Stratification factors will be ECOG Performance status (PS, 0 vs 1) and disease extension (LAD vs metastatic with presence of liver metastases vs metastatic without presence of liver metastases).

Eligibility criteria: Inclusion Criteria:

* Patient able and willing to provide written informed consent and to comply with the study protocol.
* Subjects must be ≥18 years.
* Histologically or cytologically confirmed unresectable locally advanced or metastatic pancreatic adenocarcinoma eligible for treatment in the first-line setting.
* Presence of measurable or non-measurable disease assessed by CT scan and/or MRI according to RECIST 1.1. Note: any lesion which has been subjected to percutaneous therapies or radiotherapy should not be considered measurable, unless the lesion has clearly progressed since the procedure.
* Availability of archival tumor sample (primary tumor or metastatic site) for biomarker analysis.
* ECOG performance status of 0-1 (if age \< 70 years). If age ≥70 years, ECOG PS must be 0.
* Estimated life expectancy \> 3 months.
* Adequate baseline hematologic function characterized by the following at screening:

  * Absolute Neutrophil Count (ANC) ≥ 1.5 × 109/L.
  * Platelets count ≥ 100 × 109/L.
  * Hemoglobin ≥ 9 g/dl. Note: prior transfusions for patients with low hemoglobin are allowed.
* Adequate liver function characterized by the following at screening:

  * Serum total bilirubin ≤ 1.5 × ULN and \< 2 mg/dL. Note: Subjects with Serum total bilirubin ≥ 1.5 × ULN and conjugated bilirubin ≤ ULN or \< 40% of total bilirubin are allowed.
  * Serum transaminases (AST and/or ALT) \< 3 x ULN (\< 5 x ULN in presence of liver metastasis). In participants with elevated AST or ALT, the values must be stable for at least 2 week and with no evidence of biliary obstruction by imaging.
* Adequate renal function, i.e. serum creatinine ≤ 1.5 x institutional ULN and calculated by Cockroft-Gault formula or directly measured creatinine clearance ≥ 50 mL/min.
* Adequate coagulation functions as defined by International Normalized Ratio (INR) ≤ 1.5, and a partial thromboplastin time (PTT) ≤ 5 seconds above the ULN (unless receiving anticoagulation therapy).
* No presence of complete dihydropyrimidine dehydrogenase (DPYD) enzyme deficiency (homozygous of the following DPYD polymorphisms: c1679GG, c1905+1AA, c2846TT) with DPYD gene testing mandatory at screening as per national guidelines. UDP-glucuronosyltransferase 1A1 (UGT1A1) testing is not mandatory. However, if UGT test is routinely performed in the participating centers, enrolment of patients carriers of variants of DPYD and homozygous variant UGT1A1 \[7/7\] has to be discussed with the Sponsor.
* Women of childbearing potential must agree to remain abstinent (refrain from sexual intercourse) or use highly effective contraceptive methods, as defined in APPENDIX V of the full protocol, during the treatment period and for at least 7 months after the last administration of study treatments.
* Negative serum pregnancy test within 7 days of starting study treatment in pre-menopausal women and women \<1 year after the onset of menopause.
* Men must agree to remain abstinent (refrain from sexual intercourse) or use highly effective contraceptive methods during the treatment period and for at least 7 months after the last administration of study treatments.
* Participants must agree not to donate eggs/sperm for future use for the purposes of assisted reproduction during the study and for a period of 7 months after receiving the last dose of study treatment. Female and male participants should consider preservation of eggs/sperm prior to study treatment as anti-cancer treatments may impair fertility.

Exclusion Criteria:

* Pancreatic neuroendocrine, acinar, squamous/adenosquamous, or islet tumors.
* Previous or concurrent systemic (e.g. cytotoxic or targeted or other experimental drugs) therapy for advanced pancreatic adenocarcinoma.

Note: previous (neo)adjuvant or perioperative anti-cancer therapy for non-metastatic, resectable or borderline resectable PDAC, associated with surgery on the primary tumor, is allowed if \> 9 months have elapsed from the last dose of therapy and documented disease progression or relapse.

* Major surgery or radiation therapy performed within \<4 weeks before randomization. Palliative radiotherapy to bone lesions is allowed if performed \> 2 weeks prior to start of study treatment. Patients must have recovered from an effect from major surgery.
* Known allergy or hypersensitivity to study drugs and/or their excipients.
* Unresolved toxicity ≥ CTCAE grade 2 attributed to any prior therapies (e.g. grade ≥2 peripheral neurotoxicity), excluding anemia or alopecia.
* Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that requires directed therapy (such as radiotherapy or surgery) or increasing doses of corticosteroids 2 weeks prior to study entry. Participants with treated symptomatic brain metastases should be neurologically stable for 4 weeks post-treatment and prior to study entry.
* Any known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years prior to study entry except for curatively treated basal cell carcinoma of the skin, in situ carcinoma of the cervix, and prostate cancer.
* Know active uncontrolled hepatitis B or hepatitis C. Patients with a past or resolved HBV infection are eligible. Patients with chronic disease controlled by antiviral therapy or requiring prophylactic treatment are eligible.
* Chronic or current active infectious disease requiring systemic antibiotics or antifungal treatment within 2 weeks prior to enrollment.
* Known uncontrolled HIV infection. HIV-positive patients are eligible if their CD4+ cell count amounts to 300 cells per μL or more; HIV viral load must be undetectable per standard of care assay, and patients must be compliant with antiretroviral treatment.
* Pregnant or breast-feeding patient, or patient planning to become pregnant within 7 months after the end of treatment.
* Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA \> II, unstable angina pectoris, history of myocardial infarction within 3 months before study entry, significant arrhythmia).
* Presence of psychiatric disorder precluding understanding of information of trial related topics and giving informed consent.
* Any serious underlying medical conditions (judged by the investigator), that could impair the ability of the patient to participate in the trial.

Primary outcomes:
measure: Overall Survival (OS)
timeFrame: from date of randomization to date of death (or last follow up for alive patients), assessed up to 48 months
Secondary outcomes:
measure: Progression Free Survival (PFS)
timeFrame: from randomization to disease progression or death from any cause, assessed up to 48 months
measure: Time to Treatment Failure (TTF)
timeFrame: from randomization to discontinuation of treatment for any reason, including progressive disease, treatment toxicity and death, assessed up to 48 months
measure: Objective Response Rate (ORR)
timeFrame: up to 48 months
measure: Disease Control Rate (DCR)
timeFrame: Up to approximately 48 months
measure: Quality of life (QoL)
timeFrame: Up to approximately 48 months
measure: Toxicity rate
timeFrame: Up to approximately 48 months
measure: Proportion of patients not eligible to randomization
timeFrame: Up to approximately 48 months
measure: Subsequent treatment line frequency
timeFrame: Up to approximately 48 months
Other outcomes:
Locations:
city: Aviano
country: Italy
facility: Centro Di Riferimento Oncologico Di Aviano
city: Bari
country: Italy
facility: University Hospital Consorziale Policlinico
city: Brescia
country: Italy
facility: Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
city: Crema
country: Italy
facility: ASST Ospedale Maggiore di Crema
city: Cremona
country: Italy
facility: Azienda Socio Sanitaria Territoriale Di Cremona
city: Firenze
country: Italy
facility: Careggi University Hospital
city: Genoa
country: Italy
facility: IRCCS Ospedale Policlinico San Martino
city: Meldola
country: Italy
facility: Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
city: Milan
country: Italy
facility: Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
city: Milan
country: Italy
facility: Fondazione IRCCS Istituto Nazionale dei Tumori
city: Milan
country: Italy
facility: Istituto Europeo Di Oncologia S.r.l.
city: Milan
country: Italy
facility: ASST Grande Ospedale Metropolitano Niguarda
city: Misterbianco
country: Italy
facility: Humanitas Istituto Clinico Catanese S.p.A.
city: Napoli
country: Italy
facility: Azienda Sanitaria Locale Napoli 1 Centro
city: Novara
country: Italy
facility: Azienda Ospedaliero-Universitaria Maggiore Della Carità
city: Padova
country: Italy
facility: Istituto Oncologico Veneto
city: Parma
country: Italy
facility: Azienda Ospedaliero Universitaria Parma
city: Pavia
country: Italy
facility: Fondazione IRCCS Policlinico San Matteo
city: Pesaro
country: Italy
facility: Azienda Sanitaria Territoriale Di Pesaro E Urbino
city: Pisa
country: Italy
facility: Azienda Ospedaliero Universitaria Pisana
city: Ponderano
country: Italy
facility: Azienda Sanitaria Locale Della Provincia Di Biella
city: Prato
country: Italy
facility: Azienda USL Toscana Centro
city: Ravenna
country: Italy
facility: Azienda Unita Sanitaria Locale Della Romagna
city: Rome
country: Italy
facility: I.F.O. Istituti Fisioterapici Ospitalieri
city: Rome
country: Italy
facility: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
city: Rozzano
country: Italy
facility: Humanitas Mirasole S.p.A.
city: Tricase
country: Italy
facility: Pia Fondazione Di Culto E Religione Cardinale Giovanni Panico
city: Udine
country: Italy
facility: Azienda Sanitaria Universitaria Friuli Centrale
Study officials:
affiliation: Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
name: Monica Niger, MD
role: PRINCIPAL_INVESTIGATOR
References: